House Bill No. 761, introduced by Representative Hilferty, amends R.S. 22:1076.1 to revise the composition and operational procedures of the advisory board responsible for recommending new treatments for rare cancers. The bill increases the number of oncologists on the board from two to four, expanding the expertise available for evaluating treatment options. The advisory board will continue to consist of seventeen members, including representatives from various health departments and organizations, with the executive director of the Louisiana Cancer Research Center serving as the chairperson.

Additionally, the bill modifies the reporting requirements for the advisory board. It extends the deadline for submitting formal written reports from thirty to forty-five days after each quarterly meeting and specifies that these reports must be submitted to the House Committee on Insurance and the Senate Committee on Insurance, rather than the legislature as a whole. The bill retains the existing authority for the commissioner to promulgate necessary administrative rules to implement these provisions.

Statutes affected:
HB761 Original:
HB761 Engrossed: